3 recruiting, 2 active not recruiting, 1 enrolling by invitation, 1 withdrawn. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Recruiting 2, Enrolling by invitation 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Diffuse Hemispheric Glioma, H3 G34-mutant: new trials by email Literature Review of Diffuse Hemispheric Glioma, H3 G34-mutant trials Research Report on Diffuse Hemispheric Glioma, H3 G34-mutant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 177Lu-PSMA-617 in People With Gliomas Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI - Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4) | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2025-10-27 | 2026-06-04 |
| Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma Nivolumab, Azacitidine (AZA), lumbar puncture - Glioblastoma (GBM), Diffuse Midline Glioma (DMG) | Phase 1 | Enrolling by invitation | Andrew P. Groves | 34 | 2025-06-05 | 2026-10-27 |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-12-01 | 2025-02-24 | |
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours Avutometinib, Defactinib, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 182 | 2024-11-15 | 2026-01-21 |
| 5G-EMERALD: Amivantamab in Malignant Brain Tumours Amivantamab - Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 12 | 2024-10-09 | 2026-08-17 |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Ribociclib, Everolimus, Temozolomide (TMZ) - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-08-22 | 2026-05-29 |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma Biospecimen Collection, Dendritic Cell Therapy, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 6 | 2024-06-14 | 2026-02-17 |
Glioblastoma (5) · Astrocytoma (3) · Glioma (2) · Brain Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Glioma (3) · Astrocytoma (2) · Brain Diseases (1) · Brain Stem Neoplasms (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Infratentorial Neoplasms (1) · Neoplasms by Site (1)
Temozolomide (3) · Leukapheresis (2) · Nivolumab (2) · poly ICLC (2) · Azacitidine (1) · CTLA-4 Antigen (1) · Everolimus (1) · Ipilimumab (1) · Magnetic Resonance Imaging (1) · Magnetic Resonance Spectroscopy (1) · Pluvicto (1) · Specimen Handling (1) · Spinal Puncture (1) · amivantamab (1) · defactinib (1)
Institute of Cancer Research, United Kingdom (2) · Jonsson Comprehensive Cancer Center (2) · Andrew P. Groves (1) · Memorial Sloan Kettering Cancer Center (1) · Nationwide Children's Hospital (1)
United States (5) · United Kingdom (3) · Australia (1) · Canada (1) · Germany (1) · New Zealand (1)
Juanita Lopez, MD, PhD (2) · Anthony C Wang (1) · Anthony C Wang, MD (1) · Brandon Imber, MD (1) · Margot Lazow, MD (1) · Maryam Fouladi, MD (1)